Zydus Lifesciences Sees Dual Success: USFDA Approval & Affordable CMV Drug Launch in India

s Lifesciences has achieved a significant milestone with the US Food and Drug Administration (USFDA) granting approval for its Dasatinib tablets. This medication, used to treat certain types of leukemia, will be manufactured at the company's Ahmedabad facility. Simultaneously, Zydus has launched ANVIMO (Letermovir) in India, a crucial drug for preventing Cytomegalovirus (CMV) infection in transplant patients. This launch addresses a critical need by providing a significantly more affordable alternative to previously expensive imported CMV prophylaxis drugs. ANVIMO has reduced treatment costs by 91%, making it accessible to a wider patient base. The drug ensures bioequivalence, maintaining quality while drastically improving affordability for post-transplant care. This dual achievement highlights Zydus's commitment to both global pharmaceutical standards and accessible healthcare in India.